Planta de fabricación de inyectables EU GMP en España a la venta

 

  1. BUSINESS OVERVIEW:

 

Empresa fundada en 2005 by a group of professionals from the pharmaceutical sector with the aim to manufacture and distribute healthcare and medicinal products in the hospital field.

 

  1. BUSINESS STRENGTHS:

 

The company complies with the EU GMP standard for injectible line and provide contract manufacturing servise to European pharmaceutical companies. 3 additional lines in ophtalmology is on the way to get EU GMP within 2017. Proporcionar servicios: yo) Manufacturing of liquid parenteral solutions with terminal sterilization in glass, Envase de PP, PP bags from a 50ml to 3 litres ii) Desarrollo y análisis galénico iii) Pruebas de estabilidad iv) Márketing, logística y distribución. Ventajas competitivas: yo) tax incentives due to region in Spain, ii) sin préstamos para activo iii) agua del suelo, iv) New European machineries v) lower labor costs due to region in Spain vi) possible expansion without investment

 

  1. EXPANSION OPPORTUNITY:

  1. Great possibilities for geographic expansion into Spain and other European markets, medio este, África, Asia, Americas Market whereas EU GMP is acceptable.

 

  1. 3 ophtalmology lines (1 multidose, 2 minidose) on the way to get EU GMP approval in 2017.

 

  1. 90% of factory capasities are free now, so company can rapidly grow using the existing base without additional investment.

 

  1. Own land is 5.000 sq.m., edificio 2.000 sq.m

 

 

  1. MAIN PRODUCTS (contract manufacturing services)

 

CIPROFLOXACIN 2 MG/ML, 100 ML, 200ML (Pharmaceutical)

 

FLUCONAZOL 2 MG/ML, 50 ML (Pharmaceutical)

 

METRONIDAZOL 5 MG/ML, 100 ML (Pharmaceutical)

 

STERILE WATER, 500 ML, 1000ML, 3000ML (Medical Device, CE)

 

SOLUCION NaCl 0.9 % – 50, 100, 250, 500, 1000, 3000 ML (Medical Device, CE)

 

SOLUCION GLUCOSE 1.5 %, 3000 ML (Medical Device, CE)

 

 

 

 

 

 

 

  1. MAIN CUSTOMERS:

 

Contract manufaturing servise for European pharmaceutical companies Hospitals in Spain

 

6. PROFIT AND LOSS STATEMENT, EURO  
  2016 2017
TURNOVER 300.000 600.000
OPERATING EXPENSES 360.000 360.000
PROFIT / LOSS -60.000 240.000
7. BALANCE, EURO    
ASSET 3.000.000  
LAND + BUILDING 1.500.000  
MACHINERIES 1.500.000  
NO DEBTS    

 

 

  1. DEBTS:

 

No debts.

 

 

  1. NUMBER OF EMPLOYEES: 15

  1. TAX AND LABOR LIABILITIES:

 

There is no tax liability and no labor liabilities.

 

Specifically, in the Labour domain there is no action in progress.

 

 

  1. PHISICAL AREA OF THE COMPANY:

 

España

 

 

Land 5.000
   
Building 2.000
   
Monthly Rental: No expensas, asset belongs to the company
   

 

 

 

 

 

 

 

 

 

  1. GENERAL INVENTORY:

 

Stock:

Machinery and Equipment Fixed assets:

 

 

 

 

 

1.500.000 Euro

 

 

 

  1. REASON FOR SALE:

 

Evaluating other business opportunities.

 

 

  1. SELLING PRICE AND CONDITIONS:

100% value for sale (Base date: marzo 2017) = 5.000.000 Euro

100% Cash payment

  1. ADDITIONAL INFORMATION:

Economic and financial diagnosis and companyVALUATIONwhen requested shall be provided during the DUE DILIGENCE, after expressions of interest from the investor group and signed Confidentiality Agreement (NDA).

 

  1. SALES PROCESS:

  1. Information Memorandum distribution to Pipelinepharma networking

 

  1. Investor written confirmation of interest with a LOI (letter of intent) or NBO (non-binding offer)

 

  1. Visit a plant, meeting sellers, Due Diligence

 

  1. Binding offer

 

  1. Share transfer agreement

 

 

     


    NBScience

    organización de contratos de investigación

    terapia con células madre